Products
Pre-made Conatumumab benchmark antibody ( Whole mAb, anti-TNFRSF10B/TRAIL-R2 therapeutic antibody, Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-117
Pre-Made Conatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-117-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Conatumumab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody |
| INN Name | Conatumumab |
| Target | TRAIL-R2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Amgen;Takeda |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | Colorectal cancer;Lymphoma;Non-small cell lung cancer;Pancreatic cancer;Sarcoma |
| Development Tech | Abgenix XenoMouse |
